Odronextamab BLA Accepted for FDA Review for the Treatment of Relapsed/Refractory Follicular Lymphoma
(NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for odronextamab in ...
Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update
Fourth quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $41.8 million ---- On track to report topline data from ...
Adcendo ApS Announces U.S. FDA Clearance of IND Application for Phase I Tiffany-01 Trial of ADCE-T02
Adcendo, a biotech company pioneering the development of first and best-in-class ADCs for cancers with a high unmet medical need, today announced that the U.S. Food & Drug Administration (FDA) has ...